clinical trial · NCT07224672
A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Cyclophosphamide, Bortezomib, and Dexamethasone in Adult Participants With Newly Diagnosed Amyloid Light Chain (AL) Amyloidosis
GlaxoSmithKline·phase2·not yet recruiting·n = 60
AmyloidosisBelantamab mafodotinCyclophosphamideBortezomibDexamethasone
brief summary
The study aims to evaluate the efficacy and safety of belantamab mafodotin in combination with cyclophosphamide, bortezomib, and dexamethasone in adult participants with newly diagnosed (ND) AL amyloidosis .
started
Mar 20, 2026
primary completion
Dec 13, 2032
completion
Dec 13, 2032
last updated
Mar 17, 2026
official title
A Phase 2, Open-label, Randomized, Dose Optimization Study Evaluating the Efficacy and Safety of Belantamab Mafodotin Administered in Combination With Cyclophosphamide, Bortezomib, and Dexamethasone in Adult Participants With Newly Diagnosed Amyloid Light Chain Amyloidosis (ALANIS)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol